Differences of clinical features and prognosis between Mycoplasma pneumoniae necrotizing pneumonia and non-Mycoplasma pneumoniae necrotizing pneumonia in children.

Children Clinical features Mycoplasma pneumoniae Necrotizing pneumonia Non- Mycoplasma pneumoniae

Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
10 Aug 2021
Historique:
received: 19 01 2021
accepted: 26 07 2021
entrez: 11 8 2021
pubmed: 12 8 2021
medline: 25 9 2021
Statut: epublish

Résumé

In the past few years, Mycoplasma pneumoniae (Shi et al. Lancet 390:946-958, 2017) infection has been reported more in China. However, there are few studies on the clinical characteristics and prognosis of necrotizing pneumonia (NP) (Griffiths et al. Nature 583:615-619, 2020) caused by different pathogens. A retrospective analysis was performed, including 31 children with a clinical diagnosis of NP in the hospital from January 1, 2013 to January 31, 2020. A total of 11 children with MPNP were included in the observation group and the other 20 children with other pathogens were included in the control group. The clinical manifestations, laboratory data, imaging findings, treatments and outcomes were analyzed. The proportion of dyspnea cases was significantly higher in the non-Mycoplasma pneumoniae necrotizing pneumonia (N-MPNP) group than that in the Mycoplasma pneumoniae necrotizing pneumonia (MPNP) group (P = 0.02).The LDH level of all patients in the MPNP group was higher than the normal value, with a median value of 805.0 U/L, which was significantly higher than those in the N-MPNP group (414.0 [299.9-540.6] U/L; Z =  - 2.518; P = 0.012). The white blood cells (WBCs) count of the N-MPNP group was 17.8 (11.1-21.7) × 10 1. MP infection is the most common infection in children with NP in the Suzhou area. There is no gender and age difference between MPNP and N-MPNP, but the bacterial infection was mainly observed in the N-MPNP group. 2. Children in the N-MPNP group have more severe clinical symptoms, were more prone to shortness of breath, had a longer hospital stay, and had earlier imaging manifestations of necrosis, whereas children in the MPNP group were more likely to have plastic bronchitis. The level of WBC and LDH and the nature of pleural effusion can be used to identify MPNP and N-MPNP to some extent. 3. The prognosis of MPNP was better than that of N-MPNP. There were no death cases. Pleural thickening, pulmonary fibrosis, and bronchiectasis were the most common sequelae. Compared with N-MPNP, the recovery time of lung imaging in MPNP was shorter.

Sections du résumé

BACKGROUND BACKGROUND
In the past few years, Mycoplasma pneumoniae (Shi et al. Lancet 390:946-958, 2017) infection has been reported more in China. However, there are few studies on the clinical characteristics and prognosis of necrotizing pneumonia (NP) (Griffiths et al. Nature 583:615-619, 2020) caused by different pathogens.
METHODS METHODS
A retrospective analysis was performed, including 31 children with a clinical diagnosis of NP in the hospital from January 1, 2013 to January 31, 2020. A total of 11 children with MPNP were included in the observation group and the other 20 children with other pathogens were included in the control group. The clinical manifestations, laboratory data, imaging findings, treatments and outcomes were analyzed.
RESULTS RESULTS
The proportion of dyspnea cases was significantly higher in the non-Mycoplasma pneumoniae necrotizing pneumonia (N-MPNP) group than that in the Mycoplasma pneumoniae necrotizing pneumonia (MPNP) group (P = 0.02).The LDH level of all patients in the MPNP group was higher than the normal value, with a median value of 805.0 U/L, which was significantly higher than those in the N-MPNP group (414.0 [299.9-540.6] U/L; Z =  - 2.518; P = 0.012). The white blood cells (WBCs) count of the N-MPNP group was 17.8 (11.1-21.7) × 10
CONCLUSIONS CONCLUSIONS
1. MP infection is the most common infection in children with NP in the Suzhou area. There is no gender and age difference between MPNP and N-MPNP, but the bacterial infection was mainly observed in the N-MPNP group. 2. Children in the N-MPNP group have more severe clinical symptoms, were more prone to shortness of breath, had a longer hospital stay, and had earlier imaging manifestations of necrosis, whereas children in the MPNP group were more likely to have plastic bronchitis. The level of WBC and LDH and the nature of pleural effusion can be used to identify MPNP and N-MPNP to some extent. 3. The prognosis of MPNP was better than that of N-MPNP. There were no death cases. Pleural thickening, pulmonary fibrosis, and bronchiectasis were the most common sequelae. Compared with N-MPNP, the recovery time of lung imaging in MPNP was shorter.

Identifiants

pubmed: 34376156
doi: 10.1186/s12879-021-06469-x
pii: 10.1186/s12879-021-06469-x
pmc: PMC8356421
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

797

Informations de copyright

© 2021. The Author(s).

Références

Acta Paediatr Taiwan. 2003 Nov-Dec;44(6):343-8
pubmed: 14983656
Pediatr Pulmonol. 2011 Nov;46(11):1093-7
pubmed: 21698787
Korean J Pediatr. 2014 Jun;57(6):271-7
pubmed: 25076972
BMC Infect Dis. 2020 Jun 1;20(1):391
pubmed: 32487034
Eur J Pediatr. 2006 Apr;165(4):275-7
pubmed: 16421723
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Eur Respir J. 2008 Jun;31(6):1285-91
pubmed: 18216055
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Pediatr Int. 2012 Apr;54(2):293-7
pubmed: 22507158
Can Respir J. 2014 Jul-Aug;21(4):239-45
pubmed: 24791253
Respir Investig. 2018 Mar;56(2):189-194
pubmed: 29548659
Am J Respir Crit Care Med. 1994 Jan;149(1):242-4
pubmed: 8111589
Respirology. 2013 Oct;18(7):1095-100
pubmed: 23692607
Nat Immunol. 2008 Dec;9(12):1341-6
pubmed: 18931678
Adv Exp Med Biol. 2015;857:9-17
pubmed: 25468010
Nature. 2020 Jul;583(7817):615-619
pubmed: 32494007
Pediatr Pulmonol. 2006 Jul;41(7):623-9
pubmed: 16703574
Paediatr Respir Rev. 2014 Sep;15(3):240-5; quiz 245
pubmed: 24268096
Clin Infect Dis. 2004 Mar 15;38(6):830-5
pubmed: 14999627
Pediatr Ann. 2017 Feb 1;46(2):e65-e68
pubmed: 28192581
Zhonghua Er Ke Za Zhi. 2019 Aug 2;57(8):625-630
pubmed: 31352749
Pediatr Infect Dis J. 2013 Oct;32(10):1146-9
pubmed: 23722529

Auteurs

Beilei Yang (B)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.
Department of Pediatrics, Xishan People's Hospital of Wuxi, Wuxi, 214000, China.

Weili Zhang (W)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Wenjing Gu (W)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Xinxing Zhang (X)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Meijuan Wang (M)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Li Huang (L)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Canhong Zhu (C)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Yongdong Yan (Y)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Wei Ji (W)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China.

Huiping Ni (H)

Department of Pediatrics, The Third Affiliated of Soochow University, Changzhou, 213000, China. cznihuiping@sina.com.

Zhengrong Chen (Z)

Department of Respiratory Disease, Children's Hospital of Soochow University, Suzhou, 215003, China. chenzhengrong@suda.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH